A BREAKTHROUGH TREATMENT FOR HEP C
EPCLUSA was the first Hep C therapy proven to effectively treat all six main Hep C genotypes with a simple one-pill, once-a-day treatment regimen for the majority of patients.* (See below for more information on genotypes.) This was a particularly significant advancement for patients with genotype 2 (GT2) or genotype 3 (GT3) who did not previously have a one-pill, once-a-day treatment option.
EPCLUSA is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis (compensated). In those with advanced cirrhosis (decompensated), EPCLUSA is used with ribavirin.
In clinical studies, EPCLUSA had high overall cure rates of 99% for GT2 patients† and 95% for GT3 patients.‡ EPCLUSA was also found to be highly effective in patients with GT1, GT4, GT5, and GT6, with overall cure rates ranging from 97–100%.§ Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.
With EPCLUSA, there’s no interferon and no complex regimens.
*EPCLUSA with ribavirin is recommended for patients with advanced cirrhosis (decompensated).|| If you take EPCLUSA with ribavirin, you should also read the ribavirin Medication Guide for important pregnancy-related information.
†In a study of 266 patients with genotype 2 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA or sofosbuvir + ribavirin for 12 weeks, 99% (133 out of 134) of patients who received EPCLUSA once daily for 12 weeks were cured.
‡In a study of 552 patients with genotype 3 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA for 12 weeks or sofosbuvir + ribavirin for 24 weeks, 95% (264 out of 277) of patients who received EPCLUSA once daily for 12 weeks were cured. Cure rates for EPCLUSA ranged from 89% (with prior Hep C treatment and with cirrhosis) to 98% (without prior Hep C treatment and without cirrhosis).
§In a study of 740 patients with genotype 1, 2, 4, 5, or 6 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA or placebo for 12 weeks, 98% (323 out of 328) of patients with genotype 1, 100% (116 out of 116) of patients with genotype 4, 97% (34 out of 35) of patients with genotype 5, and 100% (41 out of 41) of patients with genotype 6, who received EPCLUSA once daily for 12 weeks were cured.
These studies did not include patients with advanced cirrhosis (decompensated).||
||Advanced cirrhosis (decompensated) is when the liver is extensively scarred and can no longer do its job effectively.